Kamada Completed Manufacturing and Released the First Batch of its Plasma-Derived Immunoglobulin Product for Coronavirus Disease (COVID-19) and it is Available for Compassionate Use Treatment in Israel; Additional Production is…
Total Revenues were $33.3 Million, an Increase of 24% Year-over-Year Net Income was $5.2 Million, an Increase of 6% Year-over-Year Company Reports Continued Progress of its Development Program of a…
Rehovot, Israel, May 11, 2020 — Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the first quarter ended March 31,…
Kamada is Responsible for Product Development, Manufacturing, Clinical Development, and Regulatory Submissions, as well as Distribution in Territories not under Kedrion’s Responsibility Kedrion is Responsible for the Collection and Supply…
Rehovot, Israel, March 11, 2020 – Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial-stage plasma-derived biopharmaceutical company, today provided an update on progress related to its proprietary hyper-immunoglobulin (IgGs) product…
Total Revenues for Fiscal 2019 were $127.2 million, up 11% as Compared to 2018 Gross Profit for Fiscal 2019 was $49.7 Million, up 20% as Compared to 2018 Adjusted EBITDA…
Rehovot, Israel, February 5, 2020 — Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the fourth quarter…
Execution of Securities Purchase Agreement with FIMI Opportunity Fund, an Existing Strategic Investor, to Support Kamada’s Growth Plans and Execution of Strategic Business Opportunities Rehovot, Israel – January 21, 2020…
Full-Year 2019 Revenue Expected to be Between $126.5 Million and $127.5 Million, in-line with Company’s Prior Revenue Guidance Company Expects Full-Year 2020 Total Revenue to be Between $132 Million and…
Rehovot, Israel, December 16, 2019 — Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today that the first patient has been randomized in Europe into its…